Galenica's acquisition of Labor Team Group is anticipated to enhance its market position and drive significant sales growth in Switzerland's competitive healthcare sector.

Information on the Target

Galenica achieved a significant sales milestone in the third quarter of 2025, reporting CHF 2,999.7 million in revenue by the end of September. The company's growth was primarily driven by its 'Products & Care' and 'Logistics & IT' segments, each reflecting a 5.0% increase. Notably, the strong demand for prescription medications, particularly GLP-1-based weight loss products, alongside the sales of dietary supplements, contributed to this upward trend.

In the first half of 2025, Galenica experienced a sales increment of 5.0%. However, a slight growth deceleration was observed in the third quarter, anticipated due to an exceptionally robust performance in the previous year. The company attributes its ongoing success partly to the recent acquisition of the Labor Team Group, completed on September 9, 2025, which further bolstered its sales figures.

Industry Overview in Switzerland

The pharmaceutical sector in Switzerland has shown resilience, with the market growing by 5.1% during the same period Galenica reported its numbers. However, the consumer healthcare market faced chal